The combination of two beta-glucans produced by Aureobasidium Pullulans (AFO-202 and N-163) strains along with standard treatment was shown to reduce inflammatory biomarkers in COVID-19 patients, compared to just the standard treatment alone.
A pilot study in India has reported that intake of two strains of beta glucans can lower cytokine storm and coagulopathy biomarkers in COVID-19 patients.
A small pilot clinical study has shown that children with autism who consumed a beta-glucan food supplement for 90 days had improvements in their emotional responses and sleep patterns compared to the control group.